Impairment of TNF-α production and action by imidazo[1,2- α] quinoxalines, a derivative family which displays potential anti-inflammatory properties

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 3, 2006, Pages 525-538

  Morjaria, S ^a   Deleuze Masquefa, C ^b   Lafont, V ^a   Gayraud, S ^b   Bompart, J ^b   Bonnet, P A ^b   Dornand, Jacques ^a,c  

^a UNIV MONTPELLIER   (France)

^b Laboratoire de Pharmacochimie   (France)

^c INSERM   (France)

Author keywords

Anti inflammatory drugs; Imidazo 1,2 a quinoxalines; L 929 cell apoptosis; TNF

Indexed keywords

IMIDAZO[1,2 ALPHA] QUINOXALINE; PHOSPHODIESTERASE IV; QUINOXALINE DERIVATIVE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE;

EID: 33750085052     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200601900308     Document Type: Article

References (47)

1. Vercammen D., P. Vandenabeele, R. Beyaert, W. Declercq and W. Fiers. 1997. Tumour necrosis factor-induced necrosis versus anti-Fas-induced apoptosis in L929 cells. Cytokine 9:801.
2. Carswell E.A., L.J. Old, R.L. Kassel, S. Green, N. Fiore and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72:3666.
3. Koj A. 1996. Initiation of acute phase response and synthesis of cytokines. Biochim. Biophys. Acta 1317:84.
4. Brennan F.M. and M. Feldmann. 1996. Cytokines in autoimmunity. Curr. Opin. Immunol. 8:872.
5. Brennan F.M., R.N. Maini and M. Feldmann. 1998. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin. Immunopathol. 20:133.
6. Camussi G., C. Ronco, G. Montrucchio and G. Piccoli. 1998. Role of soluble mediators in sepsis and renal failure. Kidney Int. 66(S):38.
7. Lee J.H., N.R. Slifman, S.K. Gershon, E.T. Edwards, W.D. Schwieterman, J.N. Siegel, R.P. Wise, S.L. Brown, J.N. Udall, Jr. and M.M. Braun. 2002. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 46:2565.
8. Megyeri K., W.C. Au, I. Rosztoczy, N.B. Raj, R.L. Miller, M.A. Tomai and P.M. Pitha. 1995. Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways. Mol. Cell. Biol. 15:2207.
9. Reiter M.J., T.L. Testerman, R.L. Miller, C.E. Weeks and M.A. Tomai. 1994. Cytokine induction in mice by the immunomodulator imiquimod. J. Leukoc. Biol. 55:234.
10. Testerman T.L., J.F. Gerster, L.M. Imbertson, M.J. Reiter, R.L. Miller, S.J. Gibson, T.L. Wagner and M.A. Tomai. 1995. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. 58:365.
11. Gibson S.J., L.M. Imbertson, T.L. Wagner, T.L. Testerman, M.J. Reiter, R.L. Miller and M.A. Tomai. 1995. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Interferon Cytokine Res. 15:537.
12. Izumi T., J. Sakaguchi, M. Takeshita, H. Tawara, K. Kato, H. Dose, T. Tsujino, Y. Watanabe and H. Kato. 2003. 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-alpha suppressors: synthesis and structure-activity relationship of 1-, 2-and 4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines. Bioorg. Med. Chem. 11:2541.
13. Chen P., A.M. Doweyko, D. Norris, et al. 2004. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo-[1,5-a] pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. J. Med. Chem. 47:4517.
14. Deleuze-Masquefa C., G. Gerebtzoff, G. Subra, J.R. Fabreguettes, A. Ovens, M. Carraz, M.P. Strub, J. Bompart, P. George and P.A. Bonnet. 2004. Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors. Bioorg. Med Chem. 12:1129.
15. Gross A., M. Bouaboula, P. Casellas, J.P. Liautard and J. Dornand. 2003. Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection. J. Immunol. 170:5607.
16. Bonni A., A. Brunet, A.E. West, S.R. Datta, M.A. Takasu and M.E. Greenberg. 1999. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286:1358.
17. von Knethen A. and B. Brune. 2000. Attenuation of macrophage apoptosis by the cAMP-signaling system. Mol. Cell. Biochem. 212:35.
18. Muller Igaz L., D. Refojo, M.A. Costas, F. Holsboer and E. Arzt. 2002. CRE-mediated transcriptional activation is involved in cAMP protection of T-cell receptor-induced apoptosis but not in cAMP potentiation of glucocorticoid- mediated programmed cell death. Biochim. Biophys. Acta 1542:139.
19. Sato K., H. Nagayama, K. Tadokoro, T. Juji and T.A. Takahashi. 1999. Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J. Immunol. 162:3865.
20. Saklatvala J., J. Dean and A. Finch. 1999. Protein kinase cascades in intracellular signalling by interleukin-I and tumour necrosis factor. Biochem. Soc. Symp. 64:63.
21. Kovarik P., D. Stoiber, P.A. Eyers, R. Menghini, A. Neininger, M. Gaestel, P. Cohen and T. Decker. 1999. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc. Natl. Acad. Sci. USA 96:13956.
22. Downward J. 2004. PI 3-kinase, Akt and cell survival. Semin. Cell. Dev. Biol. 15:177.
23. Ono K. and J. Han. 2000. The p38 signal transduction pathway: activation and function. Cell. Signal. 12:1.
24. Luschen S., G. Scherer, S. Ussat, H. Ungefroren and S. Adam-Klages. 2004. Inhibition of p38 mitogen-activated protein kinase reduces TNF-induced activation of NF-kappaB, elicits caspase activity, and enhances cytotoxicity. Exp. Cell Res. 293:196.
25. Lafont V., J. Liautard, A. Gross, J.P. Liautard and J. Favero. 2000. Tumor necrosis factor-alpha production is differently regulated in gamma delta and alpha beta human T lymphocytes. J. Biol. Chem. 275:19282.
26. Lafont V., E. Astoul, A. Laurence, J. Liautard and D. Cantrell. 2000. The T cell antigen receptor activates phosphatidylinositol 3-kinase-regulated serine kinases protein kinase B and ribosomal S6 kinase 1. FEBS Lett. 486:38.
27. Lafont V., J. Liautard, M. Sable-Teychene, Y. Sainte-Marie and J. Favero. 2001. Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing down-modulation of T cell antigen receptor. J. Biol. Chem. 276:15961.
28. Lafont V., S. Loisel, J. Liautard, S. Dudal, M. Sable-Teychene, J.P. Liautard and J. Favero. 2003. Specific signaling pathways triggered by IL-2 in human V gamma 9V delta 2 T cells: an amalgamation of NK and alpha beta T cell signaling. J. Immunol. 171:5225.
29. Caron E., T. Peyrard, S. Kohler, S. Cabane, J.P. Liautard and J. Dornand. 1994. Live Brucella spp. fail to induce tumor necrosis factor alpha excretion upon infection of U937-derived phagocytes. Infect. Immun. 62:5267.
30. Ottones F., J. Dornand, A. Naroeni, J.P. Liautard and J. Favero. 2000. V gamma 9V delta 2 T cells impair intracellular multiplication of Brucella suis in autologous monocytes through soluble factor release and contact-dependent cytotoxic effect. J. Immunol. 165:7133.
31. Caron E., A. Gross, J.P. Liautard and J. Dornand. 1996. Brucella species release a specific, protease-sensitive, inhibitor of TNF-alpha expression, active on human macrophage-like cells. J. Immunol. 156:2885.
32. Jimenez de Bagues M.P., A. Gross, A. Terraza and J. Dornand. 2005. Regulation of the mitogen-activated protein kinases by Brucella spp. expressing a smooth and rough phenotype: relationship to pathogen invasiveness. Infect. Immun. 73:3178.
33. Facchinetti F., E. Del Giudice, S. Furegato, M. Passarotto and A. Leon. 2003. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41:161.
34. Delgado M., E.J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D.E. Brenneman, R. P. Gomariz and D. Ganea. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 273:31427.
35. Prabhakar U., D. Lipshutz, J.O. Bartus, M.J. Slivjak, E.F. Smith, 3rd, J.C. Lee and K.M. Esser. 1994. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16:805.
36. O'Toole A., S.K. Moule, P.J. Lockyer and A.P. Halestrap. 2001. Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308. J. Biochem. 359:119.
37. Wajant H., K. Pfizenmaier and P. Scheurich. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10:45.
38. Ono K., Y. Iwanaga, M. Hirayama, T. Kawamura, N. Sowa and K. Hasegawa. 2004. Contribution of caveolin-1 alpha and Akt to TNF-alpha-induced cell death. Am. J. Physiol. Lung Cell Mol. Physiol. 287:L201.
39. Chio C. C., Y.H. Chang, Y.W. Hsu, K.H. Chi and W.W. Lin. 2004. PKA-dependent activation of PKC, p38 MAPK and IKK in macrophage: implication in the induction of inducible nitric oxide synthase and interleukin-6 by dibutyryl cAMP. Cell. Signal. 16:565.
40. Correze C., J.P. Blondeau and M. Pomerance. 2005. p38 mitogen-activated protein kinase contributes to cell cycle regulation by cAMP in FRTL-5 thyroid cells. Eur. J. Endocrinol. 153:123.
41. Ahn Y.H., J.M. Jung and S.H. Hong. 2005. 8-Chloro-cyclic AMP-induced growth inhibition and apoptosis is mediated by p38 mitogen-activated protein kinase activation in HL60 cells. Cancer Res. 65:4896.
42. Korade-Mirnics Z. and S.J. Corey. 2000. Src kinase-mediated signaling in leukocytes. J. Leukoc. Biol. 68:603.
43. Lee J., L. Mira-Arbibe and R.J. Ulevitch. 2000. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J. Leukoc. Biol. 68:909.
44. Cipriani B., H. Knowles, L. Chen, L. Battistini and C.F. Brosnan. 2002. Involvement of classical and novel protein kinase C isoforms in the response of human V gamma 9V delta 2 T cells to phosphate antigens. J. Immunol. 169:5761.
45. Salojin K.V., J. Zhang and T.L. Delovitch. 1999. TCR and CD28 are coupled via ZAP-70 to the activation of the Vav/Rac-1-/PAK-1/p38 MAPK signaling pathway. J. Immunol. 163:844.
46. Rao K.M. 2001. MAP kinase activation in macrophages. J. Leukoc. Biol. 69:3.
47. Akira S. and H. Hemmi. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85:85.